The NACIAM Study – Assessing the benefit of N-Acetylcysteine (NAC) in acute heart attacks.

The early use of N-Acetyl Cysteine In Acute Myocardial Infarction to assess the impact of early NAC therapy in reducing myocardial infarct size as determined by Cardiac Magnetic Resonance Imaging (CMRI).

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12610000280000

Acronym

NACIAM

Enrollment

Registered

2010-04-07

Start date

2010-03-04

Completion date

2013-03-09

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

N-Acetylcysteine (NAC) is an anti-oxidant which also potentiates the action of nitroglycerine. When used with nitrates in the context of acute myocardial infarction, it may reduce infarct size by minimising reperfusion injury as well as potentiating nitroglycerine's vasodilating and anti-platelet effects. The NACIAM trial is a randomised, double-blind, placebo-controlled study assessing the impact of early NAC therapy in reducing infarct size (as assessed by cardiac MRI) in patients with acute ST elevation myocardial infarction receiving intravenous nitrate therapy and undergoing primary percutaneous coronary intervention.

Interventions

Intravenous (I.V.) N-Acetyl Cysteine (NAC) 15g or saline placebo in 500 mls 5% Dextrose delivered at 20 mg/min for 1st hour then 10 mg/min for next 47 hours. This is a one-off treatment.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Acute ST segment elevation myocardial infarction (STEMI) with primary percutaneous coronary intervention.

Exclusion criteria

Previous myocardial infarction. Permanent pacemaker or implantable defibrillator (cardiac MRI contra-indicated). Decision to administer open-label NAC for renoprotection

Outcome results